Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.

Ian E Krop Lorenza Mittempergher Joseph N PaulsonFabrice AndreHervé R Bonnefoi Sherene Loi Sibylle Loibl Richard D Gelber Carmela CaballeroRajith BhaskaranChrista DreezenAndrea R Menicucci René BernardsLaura J van 't VeerMartine J Piccart

Published in: JCO precision oncology (2024)

The 80-GS identified subgroups of histologically confirmed HER2-positive tumors with distinct biological characteristics. Basal single-subtype tumors exhibit an inferior prognosis compared with other subgroups and may be candidates for additional therapeutic strategies. Preliminary results suggest patients with HER2-positive, genomically HER2 single-subtype tumors may particularly benefit from added pertuzumab, which warrants further investigation.

Keyphrases

epidermal growth factor receptor
early stage
clinical trial
study protocol
metastatic breast cancer
genome wide
copy number
big data
phase ii
transcription factor
artificial intelligence
deep learning